April 12, 2021

The Italian Medicines Agency provides additional information on the new simplified classification procedure for generics and biosimilars

Thanks to Sofia D’Arena for collaborating on this article

On February 26, 2021, the Italian Medicines Agency (Agenzia Italiana del Farmaco, “AIFA”) provided further information on the new simplified pricing and reimbursement procedure introduced in October 2020 for generics and biosimilars. In particular, the AIFA provided clarification on cases of possible application of the automatic inclusion in Class C—without any negotiation step or prior classification in CNN—of a generic/biosimilar whose reference product (the “Originator”) is in Class C as well.

The above simplified procedure applies to medicinal products whose marketing authorization (“MA”) or line extension (“LE”) applications are submitted pursuant to Section 10, par. 1 (“generic application”), par. 3 (“hybrid application”), or par. 4 (“biosimilar application”) of Directive 2001/83/EC, implemented in Italy by Section 10, par. 1, 6, and 7 of Legislative Decree No. 219/2006, as amended from time to time.

Similarly, it also applies, to applications for Parallel Import Authorization. However, it does not apply to generic/hybrid/biosimilar medicines with therapeutic indications that go beyond those of the reference medicinal product.

The simplified procedure foresees, for the purposes of reimbursement, the classification of the abovementioned medicinal products in class C as soon as they are authorized, without prior placement in band “C Non-Negotiated” (“CNN”). As a result, it will not be necessary to further negotiate with the Health Technology Assessment (HTA) and Drug Economics Sector, nor with the Technical Scientific Committee (“Commissione Tecnico Scientifica, “CTS”)and the Pricing and Reimbursement Committee (Comitato Prezzi e Rimborso, “CPR”).

Therefore, whereas overlapping packaging means packages having the same quantity of active ingredient, pharmaceutical form, mode of administration, method of release, and dosage units, automatic classification in band C is foreseen for MA and LE applications concerning generic/hybrid/biosimilar medicinal products whose packages (i) overlap with that of an Originator that is entirely in class C; (ii) do not overlap with that of an Originator that is entirely in class C; (iii) overlap only with that of an Originator that is classified in band C, where the Originator also has different packaging reimbursed by the National Healthcare Service (band A/H).

Conversely, the new procedure does not apply to MA or LE applications concerning generic/hybrid/biosimilar medicinal products having one or more packages overlapping with those of the Originator that are reimbursed by the National Healthcare Service (Class A/H).

Please find below a table published on the AIFA website that summarizes the main cases of application of the new procedure.

The above rules will apply equally to new package applications resulting from type II or type I variations of generic/hybrid/biosimilar medicines.

In case of parallel importation applications (PIA), the packages of the medicines in question are interchangeable with those that have already been authorized for the reference medicinal product. Therefore, if the reference medicinal product is included in class C, PIA packages will automatically be included in the same class, without any prior inclusion in class CNN.

Timing for the application of the new procedure

As clarified by the AIFA, the new modalities for classification described above have been applied since the time of the CTS meeting of February 2021 (March 2021 for PIA).

As for previously authorized medicinal products, any application to pass from band CNN to band C must be submitted according to the existing procedures, since no retroactive mechanism applies.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
July 19, 2022
Guidelines for the implementation of the Electronic Health Record (EHR) to ensure dissemination, uniformity and accessibility of the EHR at national level now published in the Official Gazet...
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
Search by...
Follow us on
Follow us on